Lisata Therapeutics (LSTA) Liabilities and Shareholders Equity (2016 - 2025)
Historic Liabilities and Shareholders Equity for Lisata Therapeutics (LSTA) over the last 13 years, with Q3 2025 value amounting to $21.8 million.
- Lisata Therapeutics' Liabilities and Shareholders Equity fell 4303.78% to $21.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $110.9 million, marking a year-over-year decrease of 3963.01%. This contributed to the annual value of $35.0 million for FY2024, which is 3600.39% down from last year.
- According to the latest figures from Q3 2025, Lisata Therapeutics' Liabilities and Shareholders Equity is $21.8 million, which was down 4303.78% from $25.2 million recorded in Q2 2025.
- In the past 5 years, Lisata Therapeutics' Liabilities and Shareholders Equity registered a high of $66.3 million during Q1 2023, and its lowest value of $21.8 million during Q3 2025.
- Moreover, its 3-year median value for Liabilities and Shareholders Equity was $42.6 million (2024), whereas its average is $43.8 million.
- Per our database at Business Quant, Lisata Therapeutics' Liabilities and Shareholders Equity tumbled by 2726.83% in 2024 and then plummeted by 4303.78% in 2025.
- Lisata Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $54.7 million in 2023, then plummeted by 36.0% to $35.0 million in 2024, then tumbled by 37.83% to $21.8 million in 2025.
- Its Liabilities and Shareholders Equity was $21.8 million in Q3 2025, compared to $25.2 million in Q2 2025 and $29.0 million in Q1 2025.